Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
8.5
Expiration
Oct 23, 2026
DTE
3d
Moneyness
OTM
Intrinsic
$0.00
IBRX 8.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $1.82 | -4.71% | 11 | 223 |
| Oct 30, 2026 | 10d | $1.48 | +11.28% | 7 | 115 |
| Nov 6, 2026 | 17d | $2.20 | +37.50% | 4 | 20 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
IBRX Nearby Strikes · Oct 23, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 5.5 C | $4.27 | +55.27% | 2 | 1 | ITM |
| 6 C | $4.53 | +0.00% | 1 | 5 | ITM |
| 6.5 C | — | — | 0 | 5 | ITM |
| 7 C | $3.00 | +0.00% | 10 | 11 | ITM |
| 7.5 C | $2.47 | -14.83% | 13 | 25 | ITM |
| 8 C | $2.17 | +3.33% | 11 | 457 | ITM |
| 8.5 C | $1.82 | -4.71% | 11 | 223 | OTM |
| 9 C | $0.50 | -60.00% | 168 | 339 | OTM |
| 9.5 C | $0.28 | -65.00% | 263 | 586 | OTM |
| 10 C | $0.18 | -55.00% | 1,199 | 2,764 | OTM |
| 10.5 C | $0.15 | -57.14% | 227 | 1,476 | OTM |
| 11 C | $0.05 | -80.00% | 54 | 1,377 | OTM |
| 11.5 C | $0.05 | -82.14% | 7 | 143 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.